Shots:
- Akeso enrolled the first patient in the P-III (HARMONi-BC1/AK112-308) study of Ivonescimab + CT for the treatment of unresectable locally advanced or metastatic TNBC (already approved for EGFR-TKI-resistant, non-squamous NSCLC in China)
- The preliminary efficacy data presented at ESMO’24 showed significant therapeutic efficacy of ivonescimab + CT and a favorable safety profile for the treatment of locally advanced or metastatic TNBC
- The company reported sNDA for ivonescimab monotx. as a 1L treatment for PD-L1 + NSCLC vs pembrolizumab is currently under review and has been granted priority status in China; ivonescimab is currently being evaluated for various cancers in diff. studies
Ref: Prnewswire | Image: Akeso
Related News:- Akeso Completes Patient Enrollment in P-III (HARMONi-6/AK112-306) Trial of Ivonescimab for Squamous NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
